Spots Global Cancer Trial Database for Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer

Official Title: The Fifth Medical Center of Chinese PLA General Hospital

Study ID: NCT05018078

Conditions

Patients With Cancers

COVID-19

Vaccine

Interventions

Coronavirus vaccine

Study Description

Brief Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020. Patients with cancers may be at higher risk than those without cancer for coronavirus disease 2019 (COVID-19). At present, limited data are available on the safety and immunogenicity of COVID-19 vaccination for patients with cancer.

Detailed Description: This study is a prospective, single-arm, open-label clinical trial. A total of 300 patients with different cancers including hepatocellular carcinoma, breast cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer were included in this vaccination study. All of the patients will further accept 12 months follow-up study after vaccination. Safety and immunogenicity will be carefully recorded and detected.